The global market for clostridium vaccines for animals in categories such as bovine, ovine, cattle, and swine is swiftly expanding as the awareness regarding the various clostridial diseases and their severe impact on animal health is rising among farmers. The increasing rate of incidence of diseases associated with clostridium organisms and rising expenditure on animal health are also boosting the global demand for clostridium vaccines.
With rising demand for animal products from the rapidly expanding global population, the need for effective methods for tackling common diseases affecting livestock animals is expected to witness significant rise in the next few years. In one of its recent reports, Transparency Market Research (TMR) states that the global clostridium vaccine market (animal health) will exhibit a healthy 4.9% CAGR over the period between 2016 and 2024, rising to a valuation of US$643.5 mn by 2024 from US$418.0 mn in 2015.
In this blog post, TMR analysts answer some crucial questions associated with the market and its growth prospects:
Q. How important is vaccination against clostridial organisms in animals?
A. Clostridium bacteria are anaerobic organisms, i.e. requiring very little or no oxygen for growth, and are found in the gastrointestinal tract of animals and the soil. These bacteria only become potent cause of diseases with unusual circumstances such as parasitism, dietary stress, changes in management, and injury that develop an environment favorable to the growth of the bacteria. The bacteria produce a variety of toxins that lead to several conditions in the host body.
Commonly, clostridial diseases have a very poor prognosis and the illnesses may lead to death without showing any distinct symptoms. The rate of success of treatment is also extremely low. As a result, emphasis is usually placed on vaccination as it is the only known efficient preventive measure against diseases caused by clostridium family organisms. Clostridium vaccines enjoy widespread usage across the animal husbandry industry and can play a key role in reducing the socioeconomic impact of diseases caused by these bacteria.
Q. Which regions are most potent for excellent returns on investment in the clostridium vaccines market?
A. Presently, the global clostridium vaccines market gains a significant chunk in revenue owing to sales across North America. The region accounted for nearly 38% of the global market in 2015 and is expected to retain its dominant position in the global market in terms of contribution of revenue over the next few years as well. Presence of some of the world's leading clostridium vaccine manufacturers, significant funds granted by government bodies for research and development purposes, and an effective chain of veterinary healthcare services are the key factors to have strengthened the market for clostridium vaccines in North America.
Nevertheless, the market in Asia Pacific is expected to be the one with the most lucrative growth opportunities. The rate of growth of the Asia Pacific clostridium vaccines market is expected to outpace that of North America in the next few years. The rising awareness regarding clostridial diseases and the rising expenditure on animal health are expected to drive the market in the region.